Device Week, 8 October 2021 – Boston Scientific Acquisition, And Poor SPAC Float

In this edition of Device Week, Medtech Insight’s Reed Miller discusses Boston Scientific’s acquisition of Baylis, and what it means for its heart business. UK-based reporter Barnaby Pickering looks into LumiraDX’s recent float on the stock market, and why it might have been so poorly received.

Listen to the podcast via the player below:

 

The archive of Device Week and the rest of Informa Pharma Intelligence’s podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn, Spotify Podcasts and via smart speakers if one of these platforms has been set up as your default podcast provider.

Medtech Insight articles addressing topics discussed in this episode: 

• Boston Scientific Continues Acquisition Streak With $1.75Bn Deal For Baylis’ Cardiology Products

• LumiraDX Goes Public In SPAC Merger  (Free Article)